Lineage Cell Therapeutics Management
Management criteria checks 2/4
Lineage Cell Therapeutics' CEO is Brian Culley, appointed in Sep 2018, has a tenure of 5.67 years. total yearly compensation is $2.91M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.077% of the company’s shares, worth $157.88K. The average tenure of the management team and the board of directors is 3.3 years and 7.5 years respectively.
Key information
Brian Culley
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 22.0% |
| CEO tenure | 5.7yrs |
| CEO ownership | 0.08% |
| Management average tenure | 3.3yrs |
| Board average tenure | 7.5yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$3m | US$640k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$2m | US$609k | -US$26m |
| Sep 30 2022 | n/a | n/a | -US$49m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$3m | US$580k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$1m | US$552k | -US$21m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$36m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$773k | US$536k | -US$12m |
| Sep 30 2019 | n/a | n/a | -US$52m |
| Jun 30 2019 | n/a | n/a | US$31m |
| Mar 31 2019 | n/a | n/a | US$57m |
| Dec 31 2018 | US$3m | US$155k | -US$46m |
Compensation vs Market: Brian's total compensation ($USD2.91M) is above average for companies of similar size in the US market ($USD1.58M).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
CEO
Brian Culley (52 yo)
5.7yrs
Tenure
US$2,905,130
Compensation
Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.7yrs | US$2.91m | 0.077% $ 157.9k | |
| CFO & Principal Financial and Accounting Officer | 1.5yrs | US$738.86k | 0% $ 0 | |
| General Counsel & Company Secretary | 2.7yrs | US$1.21m | 0.0038% $ 7.8k | |
| Director of Investor Relations | no data | no data | no data | |
| Vice President of Corporate Development | less than a year | no data | no data | |
| Consultant | 3.3yrs | US$668.25k | no data | |
| President & CEO of OncoCyte Corporation | no data | US$654.85k | no data | |
| Chief Executive Officer of Cell Cure Neurosciences | no data | no data | no data | |
| Senior Director of Finance & Controller | 4.7yrs | no data | no data | |
| Vice President of Regulatory Affairs & Quality Control | 29.3yrs | US$90.00k | no data |
3.3yrs
Average Tenure
52yo
Average Age
Experienced Management: LCTX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.7yrs | US$2.91m | 0.077% $ 157.9k | |
| Independent Director | 5.2yrs | US$130.50k | 0.084% $ 173.1k | |
| Independent Director | 9.4yrs | US$138.00k | 0.046% $ 95.4k | |
| Independent Director | 3yrs | US$128.00k | 0.0053% $ 10.9k | |
| Independent Director | 14.8yrs | US$141.13k | 0.046% $ 95.5k | |
| Independent Director | 10.1yrs | US$148.00k | 0.0083% $ 17.0k | |
| Independent Chairman | 9.6yrs | US$151.13k | 0.14% $ 281.8k | |
| Independent Director | 3.1yrs | US$128.00k | 0.019% $ 38.2k |
7.5yrs
Average Tenure
62yo
Average Age
Experienced Board: LCTX's board of directors are considered experienced (7.5 years average tenure).